Although these and other authors believe in a detrimental effect of ACE inhibitors in COVID-19 patients, this assumption is still controversial, with other authors concluding that ACE inhibitors and AT1R inhibitors may reduce the lung inflammatory response and mortality and may be used in patients with COVID-19 pneumonia [48]. Here, ACE is linked to COVID-19.